Biomerica Shifts to High-Margin Diagnostics as Revenue Dips
Event summary
- inFoods® IBS real-world data shows 59.4% pain reduction and 68.1% bloating reduction in IBS patients.
- CMS sets $300 Medicare payment rate for inFoods® IBS, effective January 2026.
- European revenue up 45% YoY; hp+detect™ receives UK regulatory registration.
- R&D expenses down 24% YoY as Biomerica transitions from development to commercialization.
- Over-the-counter product line revenue grows 16% YoY.
The big picture
Biomerica is restructuring around higher-margin, diagnostically-driven products and CDMO services, reflecting a strategic shift from development to commercialization. The company's focus on IBS and H. pylori diagnostics aligns with broader trends in precision medicine and regulatory clarity for reimbursement. With real-world data supporting its products and regulatory milestones achieved, Biomerica aims to expand access and drive revenue growth in key markets.
What we're watching
- Commercial Momentum
- Whether Biomerica can sustain the 45% YoY European revenue growth and expand hp+detect™ adoption across the EU.
- Margin Expansion
- The pace at which inFoods® IBS and hp+detect™ sales scale to improve gross margins from the current 13%.
- Regulatory Headwinds
- How CMS and MHRA approvals will impact patient access and reimbursement for inFoods® IBS and hp+detect™.
Related topics